Pathology: breast cancer - adjuvant; la/mBC - HR positive; la/mBC - HR-positive - 1st line (L1); la/mBC - HR-positive - 2nd line (L2);
| breast cancer - adjuvant | la/mBC - HR positive | la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | ||||||
| PALLAS, 2022 | PENELOPE-B, 2021 | KCSG-BR15-10, 2019 | PENELOPE-B, 2021 | PALOMA-1, 2016 | PALOMA-2, 2016 | PALOMA-3, 2016 | FLIPPER, 2021 | ||
| palbociclib plus endocrine therapy | 3 | T1 | T1 | T1 | |||||
| palbociclib plus fulvestrant | 2 | T1 | T1 | ||||||
| palbociclib plus letrozole | 2 | T1 | T1 | ||||||
| palbociclib | 1 | T1 | |||||||
| endocrine therapy | 0 | T0 | T0 | T0 | |||||
| capecitabine | 0 | T0 | |||||||
| fulvestrant | 0 | T0 | T0 | ||||||
| letrozole | 0 | T0 | T0 | ||||||